TP53 and ovarian carcinoma: The crucial role of TP53 is exemplified by Li‐Fraumeni syndrome, a disorder with close to 100% cancer incidence by age 7090; the median age of ovarian cancer in these patients is 39.5 years.91 Variants have been associated with ovarian cancer risk (OR = 18.50, 95% CI 2.56‐808.1).92 However, numerous studies have not found germline TP53 variants to be significantly associated with ovarian cancer or to affect risk.61, 93, 94, 95, 96